FibroBiologics (FBLG) Announces Updates for Novel Artificial Thymus Organoid Technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
H.C. Wainwright Starts FibroBiologics (FBLG) at Buy
October 30, 2024 7:55 AM EDTH.C. Wainwright analyst Matthew Caufield initiates coverage on FibroBiologics (NASDAQ: FBLG) with a Buy rating and a price target of $12.00.
The analyst comments "Fibroblast cellular therapieslooking first to diabetic foot ulcer indication as main focus. FibroBiologics, Inc. is a clinical stage biotechnology company focused on development of fibroblast cellular therapies for chronic diseases. The companys extensive US and... More
